Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 8, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it is rescheduling its fourth quarter...
-
Mar 2, 2023
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth...
-
Dec 12, 2022
29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to...
-
Dec 5, 2022
Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022...
-
Nov 9, 2022
Data from additional patients in the TakeAim Leukemia trial of emavusertib to be presented during ASH 2022 Curis focuses its resources to drive the development of emavusertib Cash runway extended...
-
Nov 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company along with its collaborative...
-
Nov 2, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third...
-
Oct 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 3, 2022, the independent...
-
Oct 3, 2022
Symposium hosted by Guillermo Garcia-Manero, M.D.; Hagop Kantarjian, M.D.; Amit Verma, M.B.B.S. Academics and industry professionals will gather virtually on October 7, 2022 LEXINGTON, Mass., Oct....
-
Sep 19, 2022
Industry experts in immuno-oncology will gather to discuss VISTA on September 23, 2022 Symposium hosted by Randolph Noelle, Ph.D. LEXINGTON, Mass., Sept. 19, 2022 /PRNewswire/ -- Curis, Inc....
-
Sep 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
Aug 30, 2022
Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., Aug. 30, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology...
-
Aug 18, 2022
Curis working with clinical sites to resume enrollment Preliminary clinical data update expected in 2023 LEXINGTON, Mass., Aug. 18, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology...
-
Aug 4, 2022
Presented encouraging clinical data for the combination of emavusertib plus ibrutinib showing tumor reduction in 8 of 9 evaluable patients and the potential for overcoming ibrutinib resistance at...
-
Jul 29, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 22, 2022, the independent...
-
Jul 28, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second...
-
Jul 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 5, 2022, the independent...
-
Jun 10, 2022
Curis scientists discover novel IRAK4 nuclear localization and describe potential use as a biomarker IRAK4 along with NF-kB p50/p65 localization to the nucleus is associated with improved response...
-
Jun 4, 2022
TakeAim Lymphoma data for the combination of emavusertib plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses Potential for...
-
Jun 2, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief...
-
May 12, 2022
Initial TakeAim Lymphoma combination data shows anti-cancer activity, including 1 complete response and 2 partial responses, in heavily pretreated patients including those with prior ibrutinib use...
-
May 5, 2022
Strong balance sheet with $120.7 million in cash and investments at March 31, 2022; no change to cash guidance: cash runway into 2024 Potential opportunity for emavusertib in pancreatic cancer...
-
Apr 28, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first...
-
Apr 11, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration...
-
Apr 7, 2022
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 1, 2022, the independent...